White Paper

Genentech and Affimed’s $5B partnership tops the life sciences deals activity in Q3

During the third quarter of 2018, Cortellis Competitive Intelligence registered 984 new licensing deals with a total disclosed deal value of $26 billion compared to 1,060 and $20.8 billion in the second quarter and 1,158 and $33.6 billion in the third quarter of 2017. In the midst of a 23% year over year decline in licensing deals dollars, the $26 billion in total reported this quarter was primarily helped by Genentech and Affimed’s $5 billion partnership for immunotherapeutics.

We tracked 39 high-value new licensing deals worth more than $0.1 billion during the third quarter of 2018, and took a closer look at the most prolific dealmakers who are driving Q3’s licensing activity.

Complete the form opposite to get the full report.